[EN] EIF4E INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EIF4E ET LEURS UTILISATIONS
申请人:PIC THERAPEUTICS INC
公开号:WO2021178488A1
公开(公告)日:2021-09-10
The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.
本发明提供了抑制elF4E活性的化合物以及使用它们的组合物和方法。
Palladium-catalyzed direct arylation using free NH2 substituted thiophene derivatives with inhibition of amination type reaction
作者:Fazia Derridj、Karima Si Larbi、Julien Roger、Safia Djebbar、Henri Doucet
DOI:10.1016/j.tet.2012.06.053
日期:2012.9
The palladium-catalyzeddirectarylation at C2 or C5 of free NH2 substituted thiophene derivatives was found to proceed in moderate to high yields using a variety of aryl halides. The choice of potassium acetate as the base was found to be crucial to inhibit the amination reaction and to promote the directarylation.
FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
申请人:Ahmed Gulzar
公开号:US20090221555A1
公开(公告)日:2009-09-03
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
申请人:Ahmed Gulzar
公开号:US20120165519A1
公开(公告)日:2012-06-28
The present invention provides a compound of formula I or II
or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
申请人:Ahmed Gulzar
公开号:US08552186B2
公开(公告)日:2013-10-08
The present invention provides a compound of formula I or II
or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.